Zions Bancorporation N.A. Raises Stock Holdings in Sanofi (NASDAQ:SNY)

Zions Bancorporation N.A. boosted its position in shares of Sanofi (NASDAQ:SNY) by 7.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 165,350 shares of the company’s stock after acquiring an additional 10,990 shares during the quarter. Zions Bancorporation N.A.’s holdings in Sanofi were worth $7,975,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new stake in shares of Sanofi during the fourth quarter worth about $25,000. McClarren Financial Advisors Inc. lifted its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new stake in shares of Sanofi in the 4th quarter valued at $31,000. Sunbelt Securities Inc. increased its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. Finally, Sierra Ocean LLC purchased a new position in shares of Sanofi during the fourth quarter worth $44,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of Sanofi stock opened at $55.93 on Tuesday. The firm has a market cap of $141.94 billion, a PE ratio of 22.46, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $54.70 and a 200 day moving average price of $52.84.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday. They set a “neutral” rating and a $65.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.